Meglumine

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Diarrhea, Marketing, INN, Infection, Woman, Allergy, ABSSSI, ATC, Pneumonia, Aztreonam, Skin, International, Nausea, Language, Tissue, DNA, Mouth, Vancomycin, Community-acquired pneumonia, Antimicrobial spectrum, CAP, Quinolone antibiotic, Breastfeeding, European Medicines Agency, Tablet, Select, Patient, Birth, Bacteria, Anatomy, Moxifloxacin, IIA, Meglumine, Medical device

Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Quofenix, delafloxacin, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Retrieved on: 
Wednesday, February 8, 2023
NASH, Danny Galm, Patent, United States Patent and Trademark Office, Hebrew University of Jerusalem, Liver, Absorption, Liver disease, Fibrosis, Solubility, IP, Al-Quds, Meglumine, Pharmaceutical industry, Fine chemical, Aramchol

With the latest patent, Galmed is fortifying the IP protection of its lead compound, Aramchol, extending Aramchol's IP protection until end of 2038 (for its longest-term patent in US).

Key Points: 
  • With the latest patent, Galmed is fortifying the IP protection of its lead compound, Aramchol, extending Aramchol's IP protection until end of 2038 (for its longest-term patent in US).
  • Similar composition of matter patents have been granted in Canada, Europe, Australia, China, Hong-Kong, Korea, Israel, Japan and other territories for Aramchol salts.
  • Specifically, the invention provides the Aramchol amine salts and use thereof in medical treatment having advantageous physicochemical properties.
  • "This new patent which covers critical compositions of matter enhances our already robust patent portfolio, further strengthening and extending the potential commercial horizon for Aramchol," said Allen Baharaff, President and Chief Executive Officer of Galmed Pharmaceuticals.

Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP

Retrieved on: 
Tuesday, October 4, 2022
Science, Research, Pharmaceutical, Medical Supplies, Health, FDA, Medical Devices, Health Technology, NSF, Fresenius (company), Hospital, Doctor of Philosophy, Meglumine, Adult, Gadolinium, Gadoteric acid, Radiology, Pregnancy, LinkedIn, Hypersensitivity, National Center for Spinal Disorders, Magnetic resonance imaging, CEO, CT, National Center for Health Research, Multimedia, FDA, BBB, Brain, Glomerular filtration rate, Safety, Death, MRI, Headache, Agent handling, GFR, LLC, Health risk assessment, GBCA, Acute kidney injury, Patient, Rash, Diagnosis, Risk, Hypertension, USP, Nephrogenic systemic fibrosis, Spine, Nausea, Diabetes, Medical imaging, Rare-earth element, Medical device, Pharmaceutical industry, Birth control, Guerbet

Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem.

Key Points: 
  • Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem.
  • View the full release here: https://www.businesswire.com/news/home/20221004005162/en/
    Fresenius Kabi Gadoterate Meglumine Injection, USP is an FDA-approved generic for MRI procedures that is fully substitutable for Dotarem.
  • Fresenius Kabi is pleased to expand our contrast agent portfolio and our support for the radiology community with the launch of Gadoterate Meglumine Injection, USP, said John Ducker, president and CEO of Fresenius Kabi USA.
  • Contrast agents are vital to patient diagnosis, and the addition of Fresenius Kabi Gadoterate Meglumine will provide hospitals and clinics across the U.S. with more high-quality choices to support patient care.